ANTIBIOTICS MARKET ANALYSIS

Antibiotics Market, By Drug Type (Cephalosporins, Penicillins, Fluroquinilones, Macrolides, Carbapenems, Sulfonamides, Aminoglycosides, and Others), By Spectrum (Broad-Spectrum Antibiotics and Narrow-Spectrum Antibiotics), By Route of Administration (Oral, Intravenous, and Others), By Drug Origin (Natural, Semisynthetic, and Artificial), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

On January 30, 2024, Orchid Pharma Ltd., a pharmaceutical company, announced that it had received an approval from the European Medicines Agency for marketing its antibiotic 'Exblifeb,' the first completely invented-in-India Beta Lactamase inhibitor," and it is designed to address the global challenge of antimicrobial resistance (AMR)
In April 2023, Baxter International Inc., a healthcare company, launched ZOSYN in the U.S. (piperacillin and tazobactam) Injection
In October 2021, Sandoz, a Novartis AG division acquired GSK's cephalosporin antibiotics business. It now has the rights to three well-known brands (Zinnat, Zinacef, and Fortum) in 100 markets, strengthening its position as the world's leading antibiotics company.
In May 2021, Sandoz, a Novartis AG division, announced plans to further strengthen its Europe-based antibiotics manufacturing network by further expanding production capabilities in Kundl, Austria and in Palafolls, Spain. By modernizing and simplifying its manufacturing setup, Sandoz will improve its ability to consistently deliver high-quality medicines to patients, while remaining cost-competitive in the global antibiotics market.